Skip to content
Exclusive CEO Interviews
Live Interviews — Cell & Gene Meeting on the Med 2026 — onyx-live — meeting-on-the-med — cell-and-gene-therapy — bayer

Marion Hitchcock, Managing Director, Gene & Cell Therapies Incubator Berlin | Onyx Live | Cell & Gene Meeting on the Med 2026

In cell and gene therapy, the science is rarely the bottleneck – making it at scale is. Inside the Bayer–Charité incubator betting on Berlin to fix that.

Federico Citterich Federico Citterich
1 min read
Marion Hitchcock, Managing Director of the Gene & Cell Therapies Incubator Berlin
Table of Contents

When Onyx caught up with Marion Hitchcock in Rome, the conversation kept circling back to one idea: in cell and gene therapy, the science is rarely the thing that fails. Making it reliably, for thousands of patients, is.

That is the problem the Berlin Center for Gene and Cell Therapies is being built to solve. A joint venture between Bayer and Charité – Universitätsmedizin Berlin, the ten-storey site broke ground in September 2025 and is due to open in early 2028, combining plug-and-play labs, GMP-certified manufacturing and embedded expert mentorship in a single building. As its Managing Director, Hitchcock is the one shaping what that ecosystem looks like – and which early innovators it helps de-risk on the way to market.

Watch the full interview above.

At Meeting on the Med 2026, reporting for Onyx, Federico Citterich sat down with Marion Hitchcock to find out more.

A special thanks to our Onyx Live sponsors:

Cellares - delivering cell therapy manufacturing excellence at scale across a global network of IDMO smart factories https://www.cellares.com/

Comments

Related